SK Plasma Secures Investment from Indonesian Sovereign Wealth

SK Plasma, an SK Group company specializing in plasma derived medicinal products (PDMP), has completed investment from Indonesia Investment Authority. The company announced on November 14 that it has signed investment agreements with the Indonesia Investment Authority (INA) for the operation of its Indonesian joint venture, PT SKPLASMA CORE INDONESIA (SK Plasma Core).

‍

The new plant, which is scheduled to start operations in the fourth quarter of 2026, will be located in Karawang International Industrial City and will produce PDMPs such as albumin and immunoglobulin by fractionating up to 600,000 liters of plasma per year.

‍

The completion of the local fractionation plant will ensure a stable supply of medicines such as albumin, which is essential for emergency patients and surgeries, and realize self-sufficiency in plasma fractionation products, which were previously 100% imported.